Neurology

Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP

Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).

SK Biopharmaceuticals signs licensing agreement with Eurofarma for cenobamate

SK Biopharmaceuticals has signed a licensing agreement with Eurofarma, a Brazilian pharmaceutical company, to develop and commercialise cenobamate in Latin America for epilepsy treatment.

SwanBio raises $56m to advance new gene therapies for neurological conditions

SwanBio Therapeutics, a gene therapy company, has raised $56m through Series B financing round to advance gene therapies for neurological conditions.

Apnimed raises funding to advance new treatments development for OSA

Apnimed has raised $62.5m funding in a Series C round led by new investor Sectoral Asset Management to advance new pharmaceutical treatments development for obstructive sleep apnea (OSA) and related sleep disorders.

US FDA approves expanded indication for Supernus’ Qelbree for ADHD

The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.

Pfizer, Biohaven receive marketing authorisation from European Commission for Vydura

Pfizer and Biohaven Pharmaceutical have announced receipt of marketing authorisation from the European Commission (EC) for Vydura (rimegepant).

AbbVie submits sNDA to FDA for major depressive disorder therapy

AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for its therapy cariprazine (VRAYLAR) to treat major depressive disorder (MDD).

Neurimmune and Ono Pharmaceutical extend drug discovery partnership 

Neurimmune and Ono Pharmaceutical have announced the expansion of a drug discovery partnership agreement to develop antibody drugs for neurodegenerative diseases.

Pfizer, Beam sign multi-target research collaboration for rare diseases

Pfizer and Beam Therapeutics have entered into an exclusive four-year research collaboration focused on in vivo base editing programmes for three targets for rare genetic diseases of liver, central nervous system, liver and muscle.